Invasive fungal infections due to Aspergillus spp. research hub

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species

This study looks at a new medicine, olorofim, for serious fungal infections caused by Aspergillus. It compares olorofim to an existing treatment, AmBisome, to see which is safer and more effective for patients in the UK.